Drug
Denosumab clinical trials
Also written Prolia, Xgeva, AMG 162 and CT-P41.
Includes 5 studies of QL1206.
- studies test it
- 207
- open now
- 15
- in phase 3
- 72
- first study started
- 2002
Keep track of what changes. Save the Denosumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
205 studies that test it; most in 2019 (22); 2 more planned to start later
| Year | Studies |
|---|---|
| 2002 | 1 |
| 2003 | 1 |
| 2004 | 6 |
| 2005 | 1 |
| 2006 | 11 |
| 2007 | 3 |
| 2008 | 2 |
| 2009 | 10 |
| 2010 | 2 |
| 2011 | 9 |
| 2012 | 11 |
| 2013 | 10 |
| 2014 | 12 |
| 2015 | 11 |
| 2016 | 9 |
| 2017 | 19 |
| 2018 | 14 |
| 2019 | 22 |
| 2020 | 12 |
| 2021 | 13 |
| 2022 | 7 |
| 2023 | 6 |
| 2024 | 7 |
| 2025 | 6 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 5
- Phase 1
- 30
- Phase 2
- 65
- Phase 3
- 72
- Phase 4
- 39
- No phase
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 89 · Other 118
Amgen (55) · Massachusetts General Hospital (8) · Shenzhen People's Hospital (7) · Martin Blomberg Jensen (5) · Mabwell (Shanghai) Bioscience Co., Ltd. (5) · Qilu Pharmaceutical Co., Ltd. (5) · GlaxoSmithKline (5) · Celltrion (3)
Often tested with
Tested in the same studies.
Zoledronic Acid (11) · Teriparatide (5) · Alendronate (4) · Romosozumab (3) · Pamidronate (2) · Letrozole (1) · TVB-009 (1) · Calcium (1)
Studies
Open first, then newest update. How each study uses Denosumab is read from its arms, and is right about nine times in ten.
Testing it · 207
- Denosumab for Type 1 DiabetesRecruitingPhase 1/2City of Hope Medical CenterNCT06524960Written as Denosumab
- The DENOCHARCOT TrialRecruitingPhase 3Ole Lander SvendsenNCT04547348Written as Denosumab Injection
- Preserving Geriatric Muscle With an Osteoporosis MedicationRecruitingPhase 4Chrissy KistlerNCT06118905Written as Denosumab 60 MG/ML
- RANK-ligand Inhibition to Combat Sarcopenia With Underlying OsteoporosisRecruitingPhase 4Prince of Wales Hospital, Shatin, Hong KongNCT06643780Written as Denosumab
- RANKL Inhibition to Combat Sarcopenia in Hip Fracture PatientsNot yet recruitingPhase 3Prince of Wales Hospital, Shatin, Hong KongNCT07056478Written as Denosumab (Prolia)
- Sequential Treatment With Romosozumab Followed by Denosumab vs. Zoledronic Acid for Gains in HIP BMDNot yet recruitingPhase 4Sahlgrenska University HospitalNCT07772609Written as Denosumab
- Markers of Osteoporosis in Cystic FibrosisRecruitingPhase 4University of Texas Southwestern Medical CenterNCT03921060Written as Denosumab
- Bone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill AdultsRecruitingPhase 2Australian and New Zealand Intensive Care Research CentreNCT04608630Written as Denosumab 60 MG/ML
- Romosozumab and Denosumab, Alone or Combined, in Postmenopausal OsteoporosisRecruitingPhase 4National Taiwan University HospitalNCT07283887Written as Denosumab
- The Effect of Denosumab on Muscle and Strength and Insulin SensitivityRecruitingPhase 4Aarhus University HospitalNCT07271771Written as Denosumab
- A Comparative Study to Valuating the Efficacy and Safety of QL1206 and Prolia®RecruitingPhase 3Qilu Pharmaceutical Co., Ltd.NCT07062978Written as QL1206
- DEnosumab for the Treatment of FIbrous Dysplasia/McCune-Albright Syndrome in Adults (DeFiD)RecruitingPhase 4Natasha Appelman-DijkstraNCT05966064Written as Denosumab 120 Mg/1.7 Ml Inj
- Clinical Controlled Study on the Efficacy of Denosumab in Treating Osteoporosis in the Domestic Population and Its Impact on Sarcopenia-related OutcomesRecruitingPhase 3Wuhan Union Hospital, ChinaNCT06154707Written as Denosumab Injection
- Denosumab Biosimilar Injection in Post Menopausal Women With OsteoporosisRecruitingPhase 3Lambda Therapeutic Research Ltd.NCT05419427Written as Denosumab
- Denosumab Treatment in CKD Patients at High Risk of FractureRecruitingNot applicableCapital Medical UniversityNCT05692297Written as Denosumab
- Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 WeeksTerminatedPhase 3Swiss Cancer InstituteNCT02051218Written as Denosumab (reduced dosing)
- NT-NOA - Novel Treatment of Some Men With Non-Obstructive AzoospermiaCompletedPhase 1/2Martin Blomberg JensenNCT06706414Written as Denosumab (Prolia)
- RANKL Inhibition and Mammographic Breast DensityActive, not recruitingPhase 2Washington University School of MedicineNCT04067726Written as Denosumab
- Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline MutationActive, not recruitingPhase 3Alliance for Clinical Trials in OncologyNCT04711109Written as Denosumab
- A Study to Test if TVB-009P is Effective in Relieving Postmenopausal OsteoporosisCompletedPhase 3Teva Pharmaceuticals USANCT04729621Written as Prolia®
See all 207 studies that test Denosumab →
Given in every arm · 15 — Denosumab is usual care beside what is tested
- Romosozumab Versus Denosumab In Glucocorticoid-induced Osteoporosis: An Extended Observation Of a Clinical Trial at 6 YearsNot yet recruitingPhase 4Tuen Mun HospitalNCT07757373Written as Denosumab
- Study of the Key Techniques of Prevention and Treatment of Osteoporotic RefractureRecruitingNot applicablePeking Union Medical College HospitalNCT05866029Written as Denosumab
- ETC-159 In Combination With Pembrolizumab In Advanced MSS/pMMR Ovarian CancersRecruitingPhase 1National University Hospital, SingaporeNCT06513624Written as Denosumab / Zoledronic Acid
- An Exploratory Study of Tislelizumab in Combination with Chemotherapy in Immuno-experienced Patients with EGFR/ALK/ROS1-negative Advanced NSCLC in the Second-line SettingRecruitingPhase 2Shanghai Pulmonary Hospital, Shanghai, ChinaNCT06749886Written as Denosumab
- Effect of Alfacalcidol on Muscle Function in Osteoporosis PatientsNot yet recruitingPhase 4Yonsei UniversityNCT06272227Written as Denosumab
- Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab AloneActive, not recruitingPhase 4Hospital for Special Surgery, New YorkNCT04467983Written as Denosumab Injection
- Romosozumab Versus Denosumab in Glucocorticoid-induced Osteoporosis: an Extended Observation of a Randomized Controlled Trial at 48 MonthsCompletedPhase 4Tuen Mun HospitalNCT06472050Written as Denosumab
- Efficacy and Safety of Combination Denosumab With Eldecalcitol for Postmenopausal Women With Osteoporosis.(ESCORT)CompletedPhase 4Xi'an Honghui HospitalNCT05884372Written as Denosumab
- Treatment With Romosozumab Versus Denosumab to Improve Bone Mineral Density and Architecture in Subacute SCIActive, not recruitingPhase 4James J. Peters Veterans Affairs Medical CenterNCT05101018Written as Denosumab
- A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC)CompletedPhase 2Redx Pharma LtdNCT04907539Written as Denosumab
- A Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therapy (PORCUPINE2)CompletedPhase 2Redx Pharma LtdNCT04907851Written as Denosumab
- Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With OsteoporosisCompletedPhase 3AmgenNCT01575834Written as Denosumab
- Comparative Antiresorptive Efficacy Discontinuation of DenosumabActive, not recruitingPhase 4Massachusetts General HospitalNCT03623633Written as denosumab
- Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic MelanomaStatus unknownPhase 1/2Melanoma and Skin Cancer Trials LimitedNCT03161756Written as Denosumab
- Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone MetastasesTerminatedPhase 2University of HawaiiNCT02758132Written as Denosumab
As the comparator · 31 — what is tested is compared with Denosumab
- Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone MetastasisRecruitingPhase 1/2Washington University School of MedicineNCT06374459Written as Denosumab
- Denosumab Strategy for Liver Cancer With Bone MetastasesNot yet recruitingPhase 2Tongji HospitalNCT07537972Written as Denosumab
- Efficacy of Romosozumab and Denosumab Combined Treatment in Postmenopausal Osteoporosis Patients with Multiple Fragility FracturesNot yet recruitingPhase 4Marmara UniversityNCT06720350Written as Denosumab (Prolia)
- Narlumosbart Compared With Denosumab in Patients With Multiple Myeloma Bone DiseaseNot yet recruitingPhase 3RenJi HospitalNCT06314698Written as Denosumab
- A Study to Evaluate the Efficacy and Safety of Narlumosbart (JMT103) in Patients With Giant Cell Tumor of BoneNot yet recruitingPhase 3Shanghai JMT-Bio Inc.NCT05813665Written as Denosumab
- A Pharmacokinetic Similarity Study in Healthy Male Subjects to Evaluate Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of LY06006 Versus US-Prolia and EU-Prolia by Single-dose Subcutaneous InjectionCompletedPhase 1Shandong Boan Biotechnology Co., LtdNCT06095427Written as US-Prolia (Denosumab)
- Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCICompletedPhase 2VA Office of Research and DevelopmentNCT04232657Written as Denosumab
- A Phase 3 Study to Compare Biosimilar Denosumab With Prolia®CompletedPhase 3Enzene Biosciences Ltd.NCT05405725Written as Prolia
- Comparison of Efficacy, Pharmacodynamics, Safety, and Immunogenicity Between Bmab 1000 and Prolia® in Postmenopausal Women With OsteoporosisCompletedPhase 3Biocon Biologics UK LtdNCT05345691Written as Prolia®
- Single Dose, Three-arm Study to Compare the Pharmacokinetic Similarity of MAB-22 Versus Prolia®CompletedPhase 1Xentria, Inc.NCT06310824Written as EU-Prolia®
- Multicenter Study in Postmenopausal Women With Osteoporosis, ALVOBONDCompletedPhase 3Alvotech Swiss AGNCT05395091Written as Denosumab
- AVT03 With Xgeva in Healthy Male SubjectsCompletedPhase 1Alvotech Swiss AGNCT05876949Written as Denosumab
- A Study to Compare Efficacy, PK, PD, Safety and IMM of MB09 to Prolia® [EU-sourced] in Postmenopausal Osteoporosis.CompletedPhase 3mAbxience Research S.L.NCT05338086Written as EU-Prolia
- A Study to Evaluate the Efficacy, Pharmacodynamics, Safety, and Immunogenicity of FKS518 in Postmenopausal Women With OsteoporosisCompletedPhase 3Fresenius Kabi SwissBioSim GmbHNCT04934072Written as US-licensed Prolia (Amgen)
- A Study to Compare SB16 (Proposed Denosumab Biosimilar) to Prolia® in Postmenopausal Women With OsteoporosisCompletedPhase 3Samsung Bioepis Co., Ltd.NCT04664959Written as Prolia® (Denosumab)
- Study of CMAB807 Post-change in Manufacturing Site and Prolia in Healthy VolunteersCompletedPhase 1Taizhou Mabtech Pharmaceutical Co.,LtdNCT06361355Written as Prolia
- Comparative Efficacy and Safety Study of RGB-14-P and Prolia® in Women With Postmenopausal OsteoporosisCompletedPhase 3Gedeon Richter Plc.NCT05087030Written as Prolia®
- AVT03 With Prolia in Healthy Male SubjectsCompletedPhase 1Alvotech Swiss AGNCT05126784Written as Prolia
- Comparison of Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Bmab 1000 and Prolia® in Normal Healthy Volunteers: DENARIUS: DENosumab Pharmacokinetic equivAlence tRIal in Healthy volUnteerSCompletedPhase 1Biocon Biologics UK LtdNCT05323708Written as Prolia®
- Study of CMAB807X Pre- and Post-change in Manufacturing Site and Xgeva® in Healthy VolunteersWithdrawnPhase 1Taizhou Mabtech Pharmaceutical Co.,LtdNCT05808673Written as Xgeva®
Showing 20 of 31.
Codes
What other systems call Denosumab · ClinicalTrials.gg INT006582
- MeSH (NLM) D000069448DenosumabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 4EQZ6YO2HIDENOSUMABConfirmed FDA, NLM, Wikidata
- RxNorm 993449Confirmed FDA, Wikidata
- Wikidata Q408283denosumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C61313DenosumabOne source FDA
- DrugBank DB06643One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000069448 | Denosumab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 4EQZ6YO2HI | DENOSUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 993449 | — | Confirmed FDA, Wikidata |
| Wikidata | Q408283 | denosumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C61313 | Denosumab | One source FDA |
| DrugBank | DB06643 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.